BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22476430)

  • 1. Uroepithelial and kidney carcinoma in Lynch syndrome.
    Aarnio M; Säily M; Juhola M; Gylling A; Peltomäki P; Järvinen HJ; Mecklin JP
    Fam Cancer; 2012 Sep; 11(3):395-401. PubMed ID: 22476430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
    Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
    Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.
    Win AK; Lindor NM; Young JP; Macrae FA; Young GP; Williamson E; Parry S; Goldblatt J; Lipton L; Winship I; Leggett B; Tucker KM; Giles GG; Buchanan DD; Clendenning M; Rosty C; Arnold J; Levine AJ; Haile RW; Gallinger S; Le Marchand L; Newcomb PA; Hopper JL; Jenkins MA
    J Natl Cancer Inst; 2012 Sep; 104(18):1363-72. PubMed ID: 22933731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.
    van der Post RS; Kiemeney LA; Ligtenberg MJ; Witjes JA; Hulsbergen-van de Kaa CA; Bodmer D; Schaap L; Kets CM; van Krieken JH; Hoogerbrugge N
    J Med Genet; 2010 Jul; 47(7):464-70. PubMed ID: 20591884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors.
    Gylling AH; Nieminen TT; Abdel-Rahman WM; Nuorva K; Juhola M; Joensuu EI; Järvinen HJ; Mecklin JP; Aarnio M; Peltomäki PT
    Carcinogenesis; 2008 Jul; 29(7):1351-9. PubMed ID: 18550572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.
    Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M
    Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome.
    Win AK; Lindor NM; Winship I; Tucker KM; Buchanan DD; Young JP; Rosty C; Leggett B; Giles GG; Goldblatt J; Macrae FA; Parry S; Kalady MF; Baron JA; Ahnen DJ; Marchand LL; Gallinger S; Haile RW; Newcomb PA; Hopper JL; Jenkins MA
    J Natl Cancer Inst; 2013 Feb; 105(4):274-9. PubMed ID: 23385444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
    Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
    JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks of less common cancers in proven mutation carriers with lynch syndrome.
    Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF
    J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.
    Dominguez-Valentin M; Joost P; Therkildsen C; Jonsson M; Rambech E; Nilbert M
    BMC Urol; 2016 Mar; 16():15. PubMed ID: 27013479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome.
    Bozzao C; Lastella P; Ponz de Leon M; Pedroni M; Di Gregorio C; D'Ovidio FD; Resta N; Prete F; Guanti G; Stella A
    Cancer; 2011 Sep; 117(18):4325-35. PubMed ID: 21387278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upper urinary tract carcinoma in Lynch syndrome cases.
    Crockett DG; Wagner DG; Holmäng S; Johansson SL; Lynch HT
    J Urol; 2011 May; 185(5):1627-30. PubMed ID: 21419447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.
    Watson P; Vasen HFA; Mecklin JP; Bernstein I; Aarnio M; Järvinen HJ; Myrhøj T; Sunde L; Wijnen JT; Lynch HT
    Int J Cancer; 2008 Jul; 123(2):444-449. PubMed ID: 18398828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
    Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
    J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.
    Capelle LG; Van Grieken NC; Lingsma HF; Steyerberg EW; Klokman WJ; Bruno MJ; Vasen HF; Kuipers EJ
    Gastroenterology; 2010 Feb; 138(2):487-92. PubMed ID: 19900449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.
    Movahedi M; Bishop DT; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans DG; Maher ER; Bertario L; Bisgaard ML; Dunlop MG; Ho JW; Hodgson SV; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar RS; Side L; Scott RJ; Thomas HJ; Vasen HF; Burn J; Mathers JC
    J Clin Oncol; 2015 Nov; 33(31):3591-7. PubMed ID: 26282643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1.
    Lin-Hurtubise KM; Yheulon CG; Gagliano RA; Lynch HT
    J Surg Oncol; 2013 Dec; 108(7):433-7. PubMed ID: 24122742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for breast cancer as an integral part of Lynch syndrome.
    Buerki N; Gautier L; Kovac M; Marra G; Buser M; Mueller H; Heinimann K
    Genes Chromosomes Cancer; 2012 Jan; 51(1):83-91. PubMed ID: 22034109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.